ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Mental Health
On demand neuroactive nasal spray for social anxiety disorders
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 277915" data-attributes="member: 13851"><p><strong>Positive PALISADE-2 Phase 3 study of fasedienol yields statistically significant top-line results for the acute treatment of anxiety in adults with SAD</strong></p><p></p><p><em>Vistagen’s PALISADE-2 Phase 3 trial (n=141) was a U.S. multi-center, randomized, double-blind, placebo-controlled study of fasedienol in adults diagnosed with SAD. The study was designed to evaluate the efficacy, safety, and tolerability of the acute (single-dose) administration of fasedienol to relieve anxiety symptoms in adult patients with SAD during a simulated anxiety-provoking public speaking challenge in a clinical setting, as measured using the patient-reported Subjective Units of Distress Scale (SUDS).</em></p><p><em></em></p><p><em>PALISADE-2 met its primary efficacy endpoint, the difference in mean SUDS score during the public speaking challenge at baseline (Visit 2) and treatment (Visit 3) for patients who received fasedienol (n=70) versus placebo (n=71) at Visit 3. Fasedienol-treated patients demonstrated a statistically significant greater change in mean SUDS score (least-squares (LS) mean = -13.8) compared to placebo (LS mean = -8.0), for a difference between groups of -5.8 (p=0.015).</em></p><p><em></em></p><p><em>The trial also met its secondary endpoint, demonstrating a statistically significant difference in the proportion of clinician-assessed responders between fasedienol and placebo as measured by the Clinical Global Impressions Improvement (CGI-I) scale. Responders were identified as those patients who were rated ‘very much less anxious’ or ‘much less anxious’ with 37.7% (n=69) of fasedienol-treated patients rated as responders, as compared to 21.4% (n=70) of those treated with placebo (p=0.033).</em></p><p><em></em></p><p><em>Additionally, the trial met the important exploratory endpoint of the difference in the proportion of patient-assessed responders between fasedienol and placebo as measured by the Patient’s Global Impression of Change (PGI-C) scale. Responders were identified as those patients who self-rated ‘very much less anxious’ or ‘much less anxious’ with 40.6% (n=69) of fasedienol-treated patients rated as responders, as compared to 18.6% (n=70) of those treated with placebo (p=0.003).</em></p><p><em></em></p><p><em>Finally, the trial also met the exploratory endpoint of the difference in the proportion of patients in each treatment group with a 20-point improvement in patient-assessed SUDS score from baseline (Visit 2) to treatment (Visit 3). Of the fasedienol-treated patients, 35.7% (n=70) demonstrated this statistically significant and clinically meaningful improvement in SUDS score, as compared to 18.6% (n=70) in the placebo-treated group (p=0.020).</em></p><p><em></em></p><p><em><strong>Fasedienol was observed to be well-tolerated with no severe or serious adverse events (AEs) reported. All treatment-emergent AEs reported for the overall study were mild or moderate. There were no AEs reported in the fasedienol treatment arm above 2% occurrence.</strong></em></p><p><em><strong></strong></em></p><p><em><strong>Fasedienol is an investigational neuroactive pherine nasal spray with a proposed <u>rapid-onset, non-systemic MOA that sets it apart from all currently approved anti-anxiety medications</u>.</strong></em></p><p></p><p></p><p></p><p></p><p><strong>PALISADE-3 and PALISADE-4 Phase 3 clinical trials to be initiated in 2024</strong></p><p></p><p><em><strong>To complement the positive results from PALISADE-2, Vistagen is preparing to launch two similar Phase 3 clinical trials in 2024, PALISADE-3 in the first half of 2024 and PALISADE-4 in the second half of 2024.</strong> Like PALISADE-2, both PALISADE-3 and PALISADE-4 will be multi-center, randomized, double-blind, placebo-controlled, Phase 3 clinical trials designed to evaluate the efficacy, safety, and tolerability of the acute administration of fasedienol to relieve anxiety symptoms in adult patients with SAD after a single dose of fasedienol during a simulated, anxiety-provoking public speaking challenge in a clinical setting, as measured using the patient-reported SUDS as the primary efficacy endpoint. <strong>If successful, Vistagen believes either PALISADE-3 or PALISADE-4, together with PALISADE-2, <u>may establish substantial evidence of the effectiveness of fasedienol in support of a potential fasedienol NDA submission for the acute treatment of anxiety in adults with SAD with the FDA</u>.</strong></em></p></blockquote><p></p>
[QUOTE="madman, post: 277915, member: 13851"] [B]Positive PALISADE-2 Phase 3 study of fasedienol yields statistically significant top-line results for the acute treatment of anxiety in adults with SAD[/B] [I]Vistagen’s PALISADE-2 Phase 3 trial (n=141) was a U.S. multi-center, randomized, double-blind, placebo-controlled study of fasedienol in adults diagnosed with SAD. The study was designed to evaluate the efficacy, safety, and tolerability of the acute (single-dose) administration of fasedienol to relieve anxiety symptoms in adult patients with SAD during a simulated anxiety-provoking public speaking challenge in a clinical setting, as measured using the patient-reported Subjective Units of Distress Scale (SUDS). PALISADE-2 met its primary efficacy endpoint, the difference in mean SUDS score during the public speaking challenge at baseline (Visit 2) and treatment (Visit 3) for patients who received fasedienol (n=70) versus placebo (n=71) at Visit 3. Fasedienol-treated patients demonstrated a statistically significant greater change in mean SUDS score (least-squares (LS) mean = -13.8) compared to placebo (LS mean = -8.0), for a difference between groups of -5.8 (p=0.015). The trial also met its secondary endpoint, demonstrating a statistically significant difference in the proportion of clinician-assessed responders between fasedienol and placebo as measured by the Clinical Global Impressions Improvement (CGI-I) scale. Responders were identified as those patients who were rated ‘very much less anxious’ or ‘much less anxious’ with 37.7% (n=69) of fasedienol-treated patients rated as responders, as compared to 21.4% (n=70) of those treated with placebo (p=0.033). Additionally, the trial met the important exploratory endpoint of the difference in the proportion of patient-assessed responders between fasedienol and placebo as measured by the Patient’s Global Impression of Change (PGI-C) scale. Responders were identified as those patients who self-rated ‘very much less anxious’ or ‘much less anxious’ with 40.6% (n=69) of fasedienol-treated patients rated as responders, as compared to 18.6% (n=70) of those treated with placebo (p=0.003). Finally, the trial also met the exploratory endpoint of the difference in the proportion of patients in each treatment group with a 20-point improvement in patient-assessed SUDS score from baseline (Visit 2) to treatment (Visit 3). Of the fasedienol-treated patients, 35.7% (n=70) demonstrated this statistically significant and clinically meaningful improvement in SUDS score, as compared to 18.6% (n=70) in the placebo-treated group (p=0.020). [B]Fasedienol was observed to be well-tolerated with no severe or serious adverse events (AEs) reported. All treatment-emergent AEs reported for the overall study were mild or moderate. There were no AEs reported in the fasedienol treatment arm above 2% occurrence. Fasedienol is an investigational neuroactive pherine nasal spray with a proposed [U]rapid-onset, non-systemic MOA that sets it apart from all currently approved anti-anxiety medications[/U].[/B][/I] [B]PALISADE-3 and PALISADE-4 Phase 3 clinical trials to be initiated in 2024[/B] [I][B]To complement the positive results from PALISADE-2, Vistagen is preparing to launch two similar Phase 3 clinical trials in 2024, PALISADE-3 in the first half of 2024 and PALISADE-4 in the second half of 2024.[/B] Like PALISADE-2, both PALISADE-3 and PALISADE-4 will be multi-center, randomized, double-blind, placebo-controlled, Phase 3 clinical trials designed to evaluate the efficacy, safety, and tolerability of the acute administration of fasedienol to relieve anxiety symptoms in adult patients with SAD after a single dose of fasedienol during a simulated, anxiety-provoking public speaking challenge in a clinical setting, as measured using the patient-reported SUDS as the primary efficacy endpoint. [B]If successful, Vistagen believes either PALISADE-3 or PALISADE-4, together with PALISADE-2, [U]may establish substantial evidence of the effectiveness of fasedienol in support of a potential fasedienol NDA submission for the acute treatment of anxiety in adults with SAD with the FDA[/U].[/B][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Mental Health
On demand neuroactive nasal spray for social anxiety disorders
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top